MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.890
-0.010
-0.26%
After Hours: 3.900 +0.01 +0.26% 17:38 02/26 EST
OPEN
3.930
PREV CLOSE
3.900
HIGH
4.040
LOW
3.830
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
2.550
MARKET CAP
403.19M
P/E (TTM)
5.79
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Tourette Syndrome Drug Market Size 2021-2026 With Top Countries Data Share, Scope, Stake, Trends, Industry Size, Sales & Revenue, Growth, Opportunities and Demand with Competitive Landscape and Analysis Research Report | With Covid 19 Analysis
Feb 25, 2021 (The Expresswire) -- “Tourette Syndrome Drug Market” Report (2021-2026) offers a learned and top to bottom investigation on the current...
The Express Wire · 4d ago
Penny Stocks To Buy According To Analysts & Price Forecasts Up To 439%
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Rate These Penny Stocks A Buy Right Now Finding the best penny stocks to buy right now can be a tall...
Penny Stocks · 4d ago
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
marketwatch.com · 5d ago
Catalyst Pharmaceuticals Inc. stock falls Monday, still outperforms market
Shares of Catalyst Pharmaceuticals Inc. shed 1.38% to $4.28 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...
marketwatch.com · 6d ago
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The MightyCatalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-s...
GlobeNewswire · 6d ago
Catalyst Pharmaceuticals Inc. stock outperforms market on strong trading day
Shares of Catalyst Pharmaceuticals Inc. inched 0.70% higher to $4.34 Friday, on what proved to be an all-around favorable trading session for the stock...
marketwatch.com · 02/19 22:03
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Catalyst Pharmaceuticals Inc. inched 0.70% higher to $4.31 Thursday, on what proved to be an all-around grim trading session for the stock market,...
marketwatch.com · 02/18 22:02
Catalyst Pharmaceuticals Inc. stock falls Tuesday, underperforms market
Shares of Catalyst Pharmaceuticals Inc. slid 1.90% to $4.12 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the...
marketwatch.com · 02/16 22:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPRX. Analyze the recent business situations of Catalyst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPRX stock price target is 7.40 with a high estimate of 9.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 88.97M
% Owned: 85.84%
Shares Outstanding: 103.65M
TypeInstitutionsShares
Increased
39
4.80M
New
41
417.77K
Decreased
50
6.29M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/President/Director
Patrick McEnany
Chief Financial Officer/Vice President/Treasurer
Alicia Grande
Chief Operating Officer/Chief Scientific Officer
Steven Miller
Executive Vice President
David Muth
Chief Compliance Officer
Brian Elsbernd
Other
Jeffrey Del Carmen
Other
Gary Ingenito
Vice President - Business Development
David Ailinger
Lead Director/Independent Director
Charles O'Keeffe
Independent Director
Richard Daly
Independent Director
Donald Denkhaus
Independent Director
David Tierney
  • Dividends
  • Splits
  • Insider Activity
No Data
About CPRX
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.